Mainstream

Skye Bioscience signals late Q3/early Q4 top-line Phase IIa results as nimacimab advances obesity treatment platform

Skye Bioscience signals late Q3/early Q4 top-line Phase IIa results as nimacimab advances obesity treatment platform

Post ContentskyeRead More

You might also be interested in reading NuScale outlines OpEx increase and targets first U.S. SMR contract by end of 2025 as regulatory and supply chain tailwinds grow.

August 8, 2025
In Mainstream